Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 31 (5), 973-980
- https://doi.org/10.1007/s00198-019-05267-1
Abstract
A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; at years 1, 2, and 3; and at final follow-up (average of 3.4 years). Both bisphosphonate and denosumab treatments increased lumbar spine bone density; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Denosumab treatment increased femoral neck BMD, whereas bisphosphonate treatment had a mean decrease in femoral neck BMD at final follow-up. Thus, our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant. Introduction To compare the clinical effectiveness and safety between the use of denosumab and bisphosphonates on bone density and incidence of adverse events in renal transplant patients. Methods A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; years 1, 2, and 3; and at final follow-up (average of 3.4 years). Results Absolute change in lumbar spine and femoral neck BMD over the treatment period was 0.029 +/- 0.075 g/cm(2) and - 0.003 +/- 0.064 g/cm(2), respectively, in the bisphosphonate group. Absolute change in lumbar spine and femoral neck BMD at final follow-up was 0.072 +/- 0.094 g/cm(2) and 0.025 +/- 0.063 g/cm(2), respectively, in the denosumab group. Denosumab resulted in significantly greater increases in lumbar spine BMD (0.045 g/cm(2) greater in the denosumab group). Similarly, the absolute change in BMD at the femoral neck was 0.022 g/cm(2) greater in the denosumab group as compared with the bisphosphonate group. The denosumab group had one event of severe hypocalcemia following first injection and one report of hospitalized pneumonia. No serious adverse events were reported in the bisphosphonate group. Conclusions Both treatments increased lumbar spine BMD; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.Keywords
This publication has 46 references indexed in Scilit:
- Bisphosphonate Therapy and Atypical FracturesOrthopedic Clinics of North America, 2013
- Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug HolidayAmerican Journal Of Medicine, 2012
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Chapter 1: Introduction and definition of CKD–MBD and the development of the guideline statementsKidney International, 2009
- Chronic kidney disease and bone fracture: a growing concernKidney International, 2008
- Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMDJournal of Bone and Mineral Research, 2007
- Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention TrialJournal of Bone and Mineral Research, 2007
- Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical TrialsJournal of Bone and Mineral Research, 2005
- Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled StudyMayo Clinic Proceedings, 2002